Skip to main content

and
  1. No Access

    Article

    Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

    This phase 1 study (Clinicaltrials.gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib...

    S K Kumar, I Flinn, S J Noga, P Hari, R Rifkin, N Callander, M Bhandari in Leukemia (2010)

  2. Article

    Open Access

    Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells

    The purpose of the present study was to investigate the impact of the use of peripheral blood progenitor cells (PBPCs) on the induction of autologous graft-versus-host disease (GVHD) in patients with advanced ...

    E van der Wall, T Horn, E Bright, J-L Passos-Coehlo, S Bond in British Journal of Cancer (2000)